Moderna is filing for US and European emergency regulatory approval of its coronavirus vaccine so that it can be recommended for widespread use.
Regulators will look at trial data for the mRNA vaccine and decide if it is safe and effective enough to recommend for roll out.
Clinical studies show the jab is more than 94% effective at protecting people from becoming ill with Covid-19.
Pfizer, which has a similar jab, has already filed for the same US approval. UK regulators are also reviewing data on the Pfizer vaccine, as well as another type of Covid vaccine from AstraZenca and Oxford University for emergency approval. Moderna says it hopes to gain UK approval soon, now that it has trial data from 30,000 volunteers — including high risk groups like the elderly — that suggests it works.
In those studies, 15,000 people received the real vaccine while the other participants got placebo injections. No serious side effects were reported. During the studies, 185 people in the placebo group fell ill with Covid-19, and some severely so.
In comparison, there were 11 cases in the vaccine group and none were severe. Full trial data has not been released, but will be published in a peer-reviewed journal in due course.
WHO Director-General’s opening remarks at the media briefing on COVID-19–20 November 2020
More cases of COVID-19 have been reported in the past 4 weeks than in the first six months of the pandemic. This week there has been more good news from vaccine trials, which continues to give us hope of ending the pandemic.
Antimicrobial resistance may not seem as urgent as a pandemic, but it is just as dangerous.
For years, WHO has been working with the Food and Agriculture Organization of the United Nations, and the World Organisation for Animal Health, to address antimicrobial resistance and other health issues.
Today we are launching the One Health Global Leaders Group, which will bring together prominent leaders from government, the private sector and civil society organizations, to advocate for urgent action to combat the threat of antimicrobial resistance.
Good morning, good afternoon and good evening. More cases of COVID-19 have been reported in the past 4 weeks than in the first six months of the pandemic. Across Europe and North America, hospitals and ICU units are filling up or full. This week there has been more good news from vaccine trials, which continues to give us hope of ending the pandemic. At the same time, we must continue to use the tools we have to interrupt the chains of transmission and save lives now.
The COVID-19 pandemic is a stark reminder of the intimate relationship between humans, animals and the planet we share. We cannot protect and promote human health without paying attention to the health of animals and the health of our environment. That’s nowhere more true than in the case of antimicrobial resistance — one of the greatest health threats of our time.
Antimicrobial resistance may not seem as urgent as a pandemic, but it is just as dangerous. It threatens to unwind a century of medical progress and leave us defenceless against infections that today can be treated easily. Although antibiotics are a key focus, antimicrobial resistance also includes resistance to medicines for HIV, malaria, neglected tropical diseases and more.
Wednesday marked the start of World Antimicrobial Awareness Week, an annual opportunity to raise awareness of antimicrobial resistance and encourage best practices among the general public, health workers and policy makers to slow the development and spread of drug-resistant infections. The slogan for 2020 is “Antimicrobials: handle with care”.
For years, WHO has been working with the Food and Agriculture Organization of the United Nations, and the World Organisation for Animal Health, to address antimicrobial resistance and other health issues that arise from the interaction between humans and animals with a “One Health” approach. Our three organizations — called the tripartite — conduct regular surveys to monitor country progress on antimicrobial resistance.
Our latest report, with data from 136 countries, shows that almost 90% of countries have national action plans for antimicrobial resistance, but only 20% have identified funding for implementation. To help address that gap, together we have established a trust fund to support low- and middle-income countries to develop a truly One Health approach to addressing antimicrobial resistance. Thanks to the governments of the Netherlands, Sweden and the United Kingdom, to date we have raised US $13 million, which will provide the first round of support to eleven countries.
Just this week we have launched the implementation in Indonesia. Additional funds will be required for the next round of investment. Today the tripartite is launching a new report that examines the international instruments that govern the use of antimicrobials — and identifies gaps in regulations for use of antimicrobials in humans, animals and plants. Together, our three organizations will work to address these gaps and generate more global coherence in the use of antimicrobials.